Ruxolitinib (free base)
Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro.
Catalog Number | AG-CR1-3624-M025 |
Alternative Name(s) | INCB018424; INC 424 |
Research Area | Apoptosis, Autophagy, Biochemicals, Cancer, Immunology, Inflammation |
Molecular Formula | C17H18N6 |
CAS# | 941678-49-5 |
Purity | >98% |
Inchi | InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 |
Inchi Key | HFNKQEVNSGCOJV-OAHLLOKOSA-N |
SMILES | N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2 |
Size | 25 mg |
Supplier Page | http://www.adipogen.com/ag-cr1-3624/ruxolitinib.html |